The National Comprehensive Cancer Network (NCCN) updated practice guidelines for colon and rectal cancer to include BRAF mutation testing.
Results from BRAF testing, which is offered by MPLN can be utilized as an independent predictor for colorectal cancer patients' responsiveness to anti-epidermal growth factor receptor (anti-EGFR) therapy. BRAF mutation analysis also supports the exclusion of a diagnosis of hereditary non-polyposis colon cancer (HNPCC) in colorectal carcinomas that exhibit microsatellite instability (MSI-H) or loss of MLH1 protein expression.
Both the BRAF and KRAS genes are prone to mutations in sporadic colorectal cancer and are associated with shorter progressive-free survival and overall survival. Patients with BRAF or KRAS mutations, which are almost always mutually exclusive, are also less likely to respond to anti-EGFR therapy.
The updated NCCN guidelines recommend that patients with metastatic colorectal disease have BRAF gene status determined as part of their workup when the KRAS gene is not mutated. Evaluation of KRAS and BRAF are important in identifying patients who will benefit from anti-EGFR therapy. The guidelines also state that patients with a known V600E BRAF mutation should not be treated with anti-EGFR monoclonal antibodies.
BRAF testing at MPLN can be ordered as a reflex from a negative KRAS study. The MPLN KRAS mutation test detects 12 somatic mutations found in condon 12 and 13 of the KRAS oncogene.
MPLN is certified by the Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and licensed by the states of Tennessee, Florida, New York and Maryland.
For more information about the KRAS mutation test or BRAF testing, contact a client service specialist at 800.932.2943.